AKT1 (AKT Serine/Threonine Kinase 1), also known as PKB (Protein Kinase B), RAC-alpha, or PRKBA, is a key serine/threonine kinase and a core component of the PI3K-AKT-mTOR signaling pathway. It regulates critical cellular processes including proliferation, survival, metabolism, and angiogenesis. AKT1 is ubiquitously expressed, with high levels in adipose tissue, lung, and aorta. As a well-established oncogene, AKT1 is implicated in various cancers, including breast, colorectal, ovarian, and pancreatic cancers. The most common activating mutation, E17K, is found in multiple solid tumors. Drug development has evolved from pan-AKT inhibitors (e.g., capivasertib) to mutation-selective inhibitors like ALTA2618, which target AKT1 E17K to improve efficacy and reduce toxicity.